{"id":"antibody-drug-conjugate","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This mechanism involves the use of monoclonal antibodies that are engineered to bind to a specific protein on the surface of cancer cells. Once bound, the antibody is internalized by the cell, releasing a toxic payload that kills the cell. This approach allows for targeted therapy with reduced harm to healthy cells.","oneSentence":"Antibody-drug conjugates target specific cancer cells by binding to a protein on the cell surface, delivering a toxic payload to kill the cell.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:10:28.795Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Various types of cancer, including breast, lung, and ovarian cancer"}]},"trialDetails":[{"nctId":"NCT06823167","phase":"PHASE1","title":"A Phase 1 Study of IM-1021 in Participants With Advanced Cancer","status":"RECRUITING","sponsor":"Immunome, Inc.","startDate":"2025-02-26","conditions":"Solid Malignancies, Hematologic Malignancies","enrollment":117},{"nctId":"NCT01896999","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-03-07","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":146},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT07444814","phase":"PHASE1","title":"Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Whitehawk Therapeutics, Inc.","startDate":"2025-12-19","conditions":"Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic","enrollment":226},{"nctId":"NCT03606967","phase":"PHASE2","title":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-13","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma","enrollment":70},{"nctId":"NCT02166463","phase":"PHASE3","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-03-19","conditions":"Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma","enrollment":600},{"nctId":"NCT04579224","phase":"PHASE3","title":"Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-28","conditions":"Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma","enrollment":184},{"nctId":"NCT04963153","phase":"PHASE1","title":"Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-07","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma","enrollment":24},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT06015880","phase":"PHASE1","title":"Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-20","conditions":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma","enrollment":30},{"nctId":"NCT06041516","phase":"PHASE1","title":"A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-17","conditions":"Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine","enrollment":70},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","enrollment":1875},{"nctId":"NCT07043725","phase":"PHASE3","title":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-09-15","conditions":"HER2-positive Breast Cancer","enrollment":544},{"nctId":"NCT04826341","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-09-20","conditions":"HRD Cancer, SCLC, Advanced Solid Tumors","enrollment":120},{"nctId":"NCT07497074","phase":"PHASE2","title":"JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2026-04","conditions":"Cervical Cancer","enrollment":78},{"nctId":"NCT07328490","phase":"PHASE1, PHASE2","title":"Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma","enrollment":120},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT06311214","phase":"PHASE2","title":"Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-03-18","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":500},{"nctId":"NCT06524544","phase":"PHASE3","title":"A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-12-02","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":320},{"nctId":"NCT07492914","phase":"PHASE2","title":"Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-03-20","conditions":"Resected Head and Neck Cancer","enrollment":30},{"nctId":"NCT06365853","phase":"PHASE2","title":"A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-07-29","conditions":"Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive","enrollment":100},{"nctId":"NCT07205718","phase":"PHASE1, PHASE2","title":"A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-11-19","conditions":"Advanced or Metastatic Solid Tumors","enrollment":223},{"nctId":"NCT07360314","phase":"PHASE1","title":"Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-02-13","conditions":"Advanced Solid Tumors","enrollment":138},{"nctId":"NCT06926868","phase":"PHASE2, PHASE3","title":"A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-09-11","conditions":"Breast Neoplasms","enrollment":500},{"nctId":"NCT04189614","phase":"PHASE1","title":"An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-02-13","conditions":"Cancer, Non-small Cell Lung Cancer (NSCLC)","enrollment":65},{"nctId":"NCT03288545","phase":"PHASE1, PHASE2","title":"A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-10-11","conditions":"Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms","enrollment":348},{"nctId":"NCT06465069","phase":"PHASE1","title":"A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-07-01","conditions":"Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor","enrollment":420},{"nctId":"NCT04266249","phase":"PHASE2","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-03-13","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":2175},{"nctId":"NCT05123482","phase":"PHASE1, PHASE2","title":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-18","conditions":"Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer","enrollment":460},{"nctId":"NCT07487519","phase":"PHASE2","title":"Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-04-25","conditions":"Breast Cancer (Triple Negative Breast Cancer (TNBC))","enrollment":180},{"nctId":"NCT06827236","phase":"PHASE1, PHASE2","title":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-04-23","conditions":"Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer","enrollment":380},{"nctId":"NCT06994468","phase":"NA","title":"Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2025-09-22","conditions":"Membranous Nephropathy","enrollment":48},{"nctId":"NCT06641908","phase":"PHASE1","title":"Anti-GD2 ADC M3554 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2024-11-08","conditions":"Advanced Solid Tumor","enrollment":52},{"nctId":"NCT05720117","phase":"PHASE1","title":"A Study of PYX-201 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Pyxis Oncology, Inc","startDate":"2023-03-14","conditions":"Solid Tumor, Advanced Solid Tumor","enrollment":330},{"nctId":"NCT06188559","phase":"PHASE2","title":"A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2024-04-10","conditions":"Breast Cancer","enrollment":135},{"nctId":"NCT05948865","phase":"PHASE1","title":"A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Conjupro Biotherapeutics, Inc.","startDate":"2023-06-06","conditions":"Cancer, Cancer, Lung","enrollment":132},{"nctId":"NCT05748171","phase":"PHASE2","title":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-05-17","conditions":"ACUTE LYMPHOBLASTIC LEUKEMIA","enrollment":100},{"nctId":"NCT06842498","phase":"PHASE2","title":"A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Kyntra Bio","startDate":"2026-02-22","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":75},{"nctId":"NCT07213804","phase":"PHASE3","title":"A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-22","conditions":"Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms","enrollment":1080},{"nctId":"NCT07169734","phase":"PHASE1, PHASE2","title":"A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors","status":"RECRUITING","sponsor":"Alentis Therapeutics AG","startDate":"2025-08-26","conditions":"Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer","enrollment":180},{"nctId":"NCT07484022","phase":"PHASE1","title":"Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Generate Biomedicines","startDate":"2026-03","conditions":"Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma","enrollment":37},{"nctId":"NCT07090499","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-20","conditions":"Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma","enrollment":310},{"nctId":"NCT07483684","phase":"PHASE3","title":"A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":"HER2 IHC3+ Advanced Colorectal Cancer","enrollment":142},{"nctId":"NCT07286266","phase":"PHASE3","title":"A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-06-24","conditions":"Ovarian Neoplasms","enrollment":450},{"nctId":"NCT05489211","phase":"PHASE2","title":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-06","conditions":"Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":454},{"nctId":"NCT06233942","phase":"PHASE1","title":"Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2024-04-12","conditions":"Advanced Solid Tumor","enrollment":308},{"nctId":"NCT06590857","phase":"PHASE1, PHASE2","title":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.","status":"ACTIVE_NOT_RECRUITING","sponsor":"RayzeBio, Inc.","startDate":"2024-07-19","conditions":"Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer","enrollment":16},{"nctId":"NCT07480694","phase":"","title":"Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03","conditions":"Treatment Efficacy","enrollment":400},{"nctId":"NCT04143711","phase":"PHASE1, PHASE2","title":"Study of DF1001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dragonfly Therapeutics","startDate":"2019-11-11","conditions":"Solid Tumor, Adult","enrollment":270},{"nctId":"NCT05629585","phase":"PHASE3","title":"A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-11-28","conditions":"Breast Cancer","enrollment":1174},{"nctId":"NCT05464030","phase":"PHASE1","title":"Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-08-04","conditions":"Colorectal Cancer","enrollment":200},{"nctId":"NCT03384238","phase":"PHASE1, PHASE2","title":"Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery","status":"RECRUITING","sponsor":"George Poultsides","startDate":"2018-02-07","conditions":"Pancreatic Adenocarcinoma","enrollment":27},{"nctId":"NCT06649331","phase":"PHASE2","title":"Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-10-21","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC)","enrollment":160},{"nctId":"NCT06908928","phase":"PHASE1","title":"A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2025-08-11","conditions":"Triple Negative Breast Cancer","enrollment":52},{"nctId":"NCT05245006","phase":"PHASE1","title":"PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Robert Flavell, MD, PhD","startDate":"2022-03-18","conditions":"Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":30},{"nctId":"NCT06921928","phase":"PHASE1, PHASE2","title":"Study for AZD4360 in Participants With Advanced Solid Tumours","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer","enrollment":117},{"nctId":"NCT07403136","phase":"PHASE2","title":"Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-02-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":52},{"nctId":"NCT07476729","phase":"PHASE3","title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","status":"NOT_YET_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2026-04-01","conditions":"B-Cell Acute Lymphoblastic Leukaemia","enrollment":750},{"nctId":"NCT07473726","phase":"PHASE1","title":"A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-05-17","conditions":"Advanced/Metastatic Solid Tumors","enrollment":72},{"nctId":"NCT07203729","phase":"PHASE2","title":"The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03-01","conditions":"HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis","enrollment":184},{"nctId":"NCT07258407","phase":"PHASE1, PHASE2","title":"A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"T.O.A.D. Oncology SA","startDate":"2026-01-30","conditions":"Metastatic Castration-Resistant Prostatic Cancer","enrollment":180},{"nctId":"NCT07474558","phase":"PHASE2","title":"SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates","status":"NOT_YET_RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2026-09","conditions":"Advanced or Metastatic Solid Tumour, Antibody-Drug Conjugate, Alopecia","enrollment":102},{"nctId":"NCT04039230","phase":"PHASE1, PHASE2","title":"Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2019-10-09","conditions":"Breast Cancer","enrollment":75},{"nctId":"NCT04300556","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","status":"RECRUITING","sponsor":"Eisai Inc.","startDate":"2020-08-06","conditions":"Solid Tumor","enrollment":182},{"nctId":"NCT07470853","phase":"PHASE1","title":"A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.","status":"RECRUITING","sponsor":"Whitehawk Therapeutics, Inc.","startDate":"2026-03-15","conditions":"PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer","enrollment":265},{"nctId":"NCT07471776","phase":"PHASE2","title":"Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-03-11","conditions":"Metastatic Breast Cancer ( HER2 Negative)","enrollment":45},{"nctId":"NCT07082920","phase":"PHASE1","title":"A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-07-07","conditions":"Prostatic Neoplasms","enrollment":140},{"nctId":"NCT07223125","phase":"PHASE1","title":"A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-10-10","conditions":"Advanced-stage Solid Tumors","enrollment":360},{"nctId":"NCT04662580","phase":"PHASE1","title":"ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-05-03","conditions":"Metastatic Prostate Cancer","enrollment":183},{"nctId":"NCT07186842","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-11-18","conditions":"Advanced Solid Cancers","enrollment":245},{"nctId":"NCT05687266","phase":"PHASE3","title":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-12-29","conditions":"NSCLC","enrollment":1350},{"nctId":"NCT07218146","phase":"PHASE3","title":"A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)","status":"RECRUITING","sponsor":"Zai Lab (Shanghai) Co., Ltd.","startDate":"2025-11-30","conditions":"Small-cell Lung Cancer","enrollment":480},{"nctId":"NCT05865990","phase":"PHASE2","title":"HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2023-11-24","conditions":"Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult","enrollment":63},{"nctId":"NCT06057922","phase":"PHASE1, PHASE2","title":"A Study YL201 in Patients With Selected Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2023-09-22","conditions":"Advanced Solid Tumor","enrollment":990},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT06758401","phase":"PHASE3","title":"This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-07-23","conditions":"Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)","enrollment":714},{"nctId":"NCT07467629","phase":"PHASE1","title":"QLS5212 for Participants With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-04-30","conditions":"Solid Tumor Cancer","enrollment":100},{"nctId":"NCT07459673","phase":"PHASE2","title":"HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-03-04","conditions":"Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage IV","enrollment":60},{"nctId":"NCT07144280","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-09-29","conditions":"Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma","enrollment":680},{"nctId":"NCT07466303","phase":"PHASE2","title":"Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2026-03-25","conditions":"Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer","enrollment":84},{"nctId":"NCT07070232","phase":"PHASE1, PHASE2","title":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-08-12","conditions":"Advanced Solid Tumor","enrollment":980},{"nctId":"NCT05460273","phase":"PHASE1, PHASE2","title":"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-07-11","conditions":"Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Cancer","enrollment":119},{"nctId":"NCT07286331","phase":"PHASE3","title":"A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-06-09","conditions":"Neoplasms, Endometrial","enrollment":600},{"nctId":"NCT06384807","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Biohaven Therapeutics Ltd.","startDate":"2024-04-22","conditions":"Solid Tumor","enrollment":500},{"nctId":"NCT07229313","phase":"PHASE1","title":"A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Kivu Bioscience Inc.","startDate":"2025-11-13","conditions":"Advance Solid Tumors","enrollment":76},{"nctId":"NCT06048718","phase":"PHASE2","title":"T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2024-06-05","conditions":"Breast Cancer, Metastatic Breast Cancer","enrollment":28},{"nctId":"NCT07460375","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"LigaChem Biosciences, Inc.","startDate":"2026-08","conditions":"Advanced Solid Tumors","enrollment":191},{"nctId":"NCT07459738","phase":"PHASE2","title":"A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-04-01","conditions":"Hormone Receptor Positive HER-2 Negative Breast Cancer","enrollment":60},{"nctId":"NCT04829604","phase":"PHASE2","title":"ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ambrx, Inc.","startDate":"2021-10-26","conditions":"HER2 Positive Metastatic Breast Cancer","enrollment":72},{"nctId":"NCT07099898","phase":"PHASE3","title":"A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-08-11","conditions":"Neoplasms, Lung","enrollment":420},{"nctId":"NCT07455045","phase":"PHASE1","title":"A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","startDate":"2026-03-01","conditions":"High Grade Glioma (III or IV), Diffuse Midline Glioma (DMG), Glioblastoma (GBM)","enrollment":40},{"nctId":"NCT07164313","phase":"PHASE1","title":"A Study of ZW251 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Zymeworks BC Inc.","startDate":"2025-10-21","conditions":"Hepatocellular Carcinoma","enrollment":100},{"nctId":"NCT06710132","phase":"PHASE1, PHASE2","title":"Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2025-01-29","conditions":"Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC)","enrollment":250},{"nctId":"NCT07181161","phase":"PHASE1, PHASE2","title":"Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-10-01","conditions":"Metastatic Prostate Cancer","enrollment":177},{"nctId":"NCT06555744","phase":"PHASE1","title":"A Study of ZW191 in Participants With Solid Tumors","status":"RECRUITING","sponsor":"Zymeworks BC Inc.","startDate":"2024-10-30","conditions":"Advanced Solid Tumors","enrollment":145},{"nctId":"NCT07268053","phase":"EARLY_PHASE1","title":"A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases","status":"RECRUITING","sponsor":"Nader Sanai","startDate":"2026-02-11","conditions":"Glioblastoma (GBM), Brain Metastasases","enrollment":15},{"nctId":"NCT07227168","phase":"PHASE1","title":"A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer","status":"RECRUITING","sponsor":"Sutro Biopharma, Inc.","startDate":"2025-11-07","conditions":"Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer","enrollment":200},{"nctId":"NCT06857279","phase":"PHASE2","title":"A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-04-22","conditions":"Carcinoma of Head and/or Neck","enrollment":167},{"nctId":"NCT03260491","phase":"PHASE1","title":"U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2017-10-30","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":312}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4844,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Antibody-Drug Conjugate","genericName":"Antibody-Drug Conjugate","companyName":"Sung-Soo Park","companyId":"sung-soo-park","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antibody-drug conjugates target specific cancer cells by binding to a protein on the cell surface, delivering a toxic payload to kill the cell. Used for Various types of cancer, including breast, lung, and ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}